TY - JOUR
T1 - Acetylcholinesterase inhibitors (nerve agents) as weapons of mass destruction
T2 - History, mechanisms of action, and medical countermeasures
AU - Aroniadou-Anderjaska, Vassiliki
AU - Apland, James P.
AU - Figueiredo, Taiza H.
AU - De Araujo Furtado, Marcio
AU - Braga, Maria F.
N1 - Publisher Copyright:
© 2020
PY - 2020/12/15
Y1 - 2020/12/15
N2 - Nerve agents are organophosphorus acetylcholinesterase inhibitors. Acute exposure to nerve agents can cause rapid death. In this review, we summarize the history of nerve agent development and use in warfare, the mechanisms by which these agents cause death or long-term brain damage, and the treatments for preventing death or long-term morbidity. The G-series nerve agents, tabun, sarin, soman, ethyl sarin, and cyclosarin, were developed by the Nazis. VX, the best-known of the V-series agents, was synthesized in the 1950's by a British scientist. Little is known about the development of the novichoks (the “A-series”) by the former Soviet Union. Nerve agents were used for the first time in the battlefield by the Iraqi government in the Iran–Iraq War, in the 1980s. The Chemical Weapons Convention, in 1993, banned all chemical weapons production and use, yet, sarin was subsequently used in terrorist attacks in Japan and, recently, in the war in Syria. Pyridostigmine has been used as a prophylactic treatment, and bioscavengers are presently investigated as a better alternative. Atropine, along with an oxime, can prevent rapid death from the nerve agent-induced peripheral cholinergic crisis. Treatment with diazepam or midazolam for the cessation of nerve agent-induced status epilepticus cannot protect against brain damage, and, therefore, these benzodiazepines should be replaced by novel anticonvulsants and neuroprotectants. The AMPA/GluK1 receptor antagonist LY293558 (tezampanel) has shown superior antiseizure and neuroprotective efficacy against soman, particularly when administered in combination with caramiphen, an antagonist of muscarinic and NMDA receptors.
AB - Nerve agents are organophosphorus acetylcholinesterase inhibitors. Acute exposure to nerve agents can cause rapid death. In this review, we summarize the history of nerve agent development and use in warfare, the mechanisms by which these agents cause death or long-term brain damage, and the treatments for preventing death or long-term morbidity. The G-series nerve agents, tabun, sarin, soman, ethyl sarin, and cyclosarin, were developed by the Nazis. VX, the best-known of the V-series agents, was synthesized in the 1950's by a British scientist. Little is known about the development of the novichoks (the “A-series”) by the former Soviet Union. Nerve agents were used for the first time in the battlefield by the Iraqi government in the Iran–Iraq War, in the 1980s. The Chemical Weapons Convention, in 1993, banned all chemical weapons production and use, yet, sarin was subsequently used in terrorist attacks in Japan and, recently, in the war in Syria. Pyridostigmine has been used as a prophylactic treatment, and bioscavengers are presently investigated as a better alternative. Atropine, along with an oxime, can prevent rapid death from the nerve agent-induced peripheral cholinergic crisis. Treatment with diazepam or midazolam for the cessation of nerve agent-induced status epilepticus cannot protect against brain damage, and, therefore, these benzodiazepines should be replaced by novel anticonvulsants and neuroprotectants. The AMPA/GluK1 receptor antagonist LY293558 (tezampanel) has shown superior antiseizure and neuroprotective efficacy against soman, particularly when administered in combination with caramiphen, an antagonist of muscarinic and NMDA receptors.
KW - Caramiphen
KW - Diazepam
KW - LY293558
KW - Midazolam
KW - Nerve agents
KW - Status epilepticus
UR - http://www.scopus.com/inward/record.url?scp=85092894636&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2020.108298
DO - 10.1016/j.neuropharm.2020.108298
M3 - Review article
C2 - 32898558
AN - SCOPUS:85092894636
SN - 0028-3908
VL - 181
JO - Neuropharmacology
JF - Neuropharmacology
M1 - 108298
ER -